Clinical Trials Logo

Advanced Cancers clinical trials

View clinical trials related to Advanced Cancers.

Filter by:

NCT ID: NCT02597478 Completed - Advanced Cancers Clinical Trials

Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea

Start date: January 4, 2016
Phase: Phase 2/Phase 3
Study type: Interventional

The goal of this clinical research study is to learn if fentanyl can help shortness of breath in cancer patients. Researchers also want to learn if the study drug can help to improve your physical function.

NCT ID: NCT02571036 Completed - Clinical trials for Gastrointestinal Stromal Tumors

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

Start date: November 2015
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of DCC-2618, administered orally (PO), in adult patients with advanced malignancies. The study consists of 2 parts, a dose-escalation phase, and an expansion phase. All active patients (from both dose-escalation and expansion phases) will then transition into an extension phase.

NCT ID: NCT02561234 Completed - Advanced Cancers Clinical Trials

A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors

Start date: October 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This is the first-in-human study of the safety of increasing dose levels of AEB1102 in patients with advanced cancers. The study will also evaluate the amounts of AEB1102 in blood, the effects of AEB1102 on blood amino acid levels and tumor growth.

NCT ID: NCT02558257 Completed - Advanced Cancers Clinical Trials

Perception of Palliative Care Encounter

Start date: August 16, 2015
Phase:
Study type: Observational

Objectives: Primary Objective The primary objective is to determine patients' perceptions of the timeliness of their referral to an outpatient palliative care clinic. The secondary objectives are to determine: 1. The factors and variables associated with perception of timeliness such as age, gender, and symptom distress 2. The patients' perceptions of the physical environment of the outpatient clinic at UT MD Anderson Cancer Center (UTMDACC) such as lighting, music, and lack of a waiting room; and 3. If there is an association between level of distress (physical, psychological, and spiritual distress as measured by Edmonton Symptom Assessment Scale (ESAS) and the usefulness of the referral to palliative care center.

NCT ID: NCT02523378 Completed - Advanced Cancers Clinical Trials

Edmonton Symptom Assessment Scale: Self-Completion vs. Assisted-Completion

Start date: August 13, 2015
Phase: N/A
Study type: Interventional

The goal of this research study is to learn how easy participants think it is to complete a symptom questionnaire.

NCT ID: NCT02521194 Terminated - Advanced Cancers Clinical Trials

Occupational Therapy in Palliative Care

Start date: November 13, 2015
Phase: N/A
Study type: Interventional

The goal of this research study is to learn if inpatient occupational therapy can help patients in the Palliative Care Unit (PCU).

NCT ID: NCT02514252 Terminated - Advanced Cancers Clinical Trials

Sublingual Fentanyl for the Management of Breakthrough Pain

Start date: February 2, 2016
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if an investigational dose of fentanyl sublingual spray (FSS) can help to control pain in patients with advanced cancer when given in an outpatient and inpatient setting.

NCT ID: NCT02508662 Completed - Solid Tumors Clinical Trials

Registry Study for Personalized Cancer Therapy

Start date: July 21, 2015
Phase:
Study type: Observational

Objectives: Primary Objectives: To evaluate the anti-cancer activity of commercially available, targeted anti-cancer therapies used off-label for treatment in patients with advanced solid cancer with known genomic aberrations. Secondary Objectives: To determine outcomes of patients who were treated with matched targeted anti-cancer therapies based on known genomic aberrations. To obtain treatment related adverse events in patients with advanced solid tumor who were treated with off -label targeted therapies. To determine co-genomic aberrations that may contribute to treatment response or resistance mechanisms. To determine feasibility of detecting the genomic alterations in plasma, and the genomic evolution of circulating biomarkers.

NCT ID: NCT02498899 Completed - Advanced Cancers Clinical Trials

Message 2: The Effect of Message Content and Clinical Outcome on Patient's Perception of Physician Compassion

Start date: July 2015
Phase: N/A
Study type: Interventional

The goal of this research study is to learn how patients view their doctor's compassion about supportive care and treatment options for advanced cancer patients.

NCT ID: NCT02478320 Terminated - Advanced Cancers Clinical Trials

Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors

Start date: August 5, 2016
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if ilorasertib (ABT-348) can help to control CDKN2A-deficient cancer. CDKN2A deficiency is a type of mutation (a genetic change). The safety of this drug will also be studied.